Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Market Size of the Humira Biosimilar Market In 2029?
The market size for Humira biosimilars has seen a significant expansion in the previous years. The market, valued at $3.28 billion in 2024, is projected to increase to $3.67 billion in 2025, reflecting a compound annual growth rate (CAGR) of 12.0%. This remarkable growth during the historic period is a result of several factors. These include the escalating demand for economical substitutes, the rising number of biosimilars approved by regulatory authorities, an increased prevalence of autoimmune conditions, the broadening of access to healthcare in developing markets, and the substantial cost of original biologics.
The market for Humira biosimilars is projected to experience substantial expansion in the coming years, reaching an expected value of$5.82 billion in 2029 with a compound annual growth rate (CAGR) of 12.3%. The progression throughout the predicted period is tied to enhancements in biosimilar development technology, intensified efforts in constraining healthcare costs, the extension of original biologics’ patent expirations, improvement in market accessibility and reimbursement policies, along with the growing application of biosimilars in fields like oncology and autoimmune diseases. The forecast period will likely witness an escalating approval rate for more biosimilars, advancements in biomanufacturing processes, increasing research and development initiatives, the development and subsequent approval of biosimilar drugs, and progress in drug formulation.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24244&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Humira Biosimilar Market?
The escalating incidence of autoimmune diseases is anticipated to drive the expansion of the humira biosimilar market. Autoimmune diseases are conditions where the body’s immune system erroneously fights and destroys healthy cells, tissues, or organs of the body. The rise in these diseases is linked to environmental pollution, which interferes with the immune system’s function, thereby increasing the chances of autoimmune reactions. Humira biosimilars function by blocking the tumor necrosis factor (TNF), which instigates inflammation in autoimmune conditions. They help to mitigate immune responses, easing symptoms and averting any harm to healthy tissues. According to the Australian Institute of Health and Welfare, a governmental organization based in Australia, data from June 2024 showed that in 2022 there were around 514,000 individuals, accounting for 2.0% of the population in Australia diagnosed with rheumatoid arthritis, affecting more females (2.5%) than males (1.6%). Thus, the growing occurrence of autoimmune diseases is accelerating the growth of the humira biosimilar market.
Which Primary Segments of the Humira Biosimilar Market Are Driving Growth and Industry Transformations?
The humira biosimilarmarket covered in this report is segmented –
1) By Product Type: Adalimumab Biosimilars; Other Types
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
3) By Application: Rheumatoid Arthritis; Psoriasis; Crohn’s Disease; Ulcerative Colitis; Ankylosing Spondylitis; Other Applications
Subsegments:
1) By Adalimumab Biosimilars: Fully Human Monoclonal Antibodies; Fragment Crystallizable (Fc) Region Modified Biosimilars; High-Concentration Formulations; Citrate-Free Formulations
2) By Other Types: Biosimilars Of Other Tumor Necrosis Factor (TNF) Inhibitors; Interchangeable Biosimilars; Pegylated Biosimilars; Non-Adalimumab Monoclonal Antibody Biosimilars
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=24244&type=smp
Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Humira Biosimilar Market?# Market?
North America was the largest region in the humira biosimilar market in 2024. The regions covered in the humira biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Most Significant Market Trends in the Humira Biosimilar Market?
The key players in the humira biosimilar market are striving to formulate superior products such as tumor necrosis factor (TNF) blockers to present cost-effective solutions for the management of autoimmune diseases. Biologic medications like tumor necrosis factor (TNF) blockers counteract the activity of TNF, an influential protein which fosters inflammation. For example, in July 2023, Organon & Co., a pharmaceutical corporation based in the U.S., teamed up with Samsung Bioepis Co., Ltd., a biotech firm from South Korea, to introduce HADLIMA, a humira biosimilar. As an attempt to enhance patient accessibility and cost-effectiveness, HADLIMA is offered both in citrate-free high-concentration (100 mg/mL) and citrate inclusive low-concentration (50 mg/mL) forms, equivalent to the original Humira options. The product, which comes with patient support programs, is priced significantly lower, approximately 85% less than Humira’s listed price. This introduction, which follows a worldwide agreement enabling U.S. supply, marks a prominent advancement in broadening therapeutic options for chronic autoimmune diseases in the U.S.
View the full report here:
https://www.thebusinessresearchcompany.com/report/humira-biosimilar-global-market-report
What Parameters Are Used to Define the Humira Biosimilar Market?
A Humira biosimilar is a biologic drug developed to closely replicate humira in treating autoimmune disorders. It matches the original in safety, effectiveness, and quality but is typically more affordable. By offering a cost-effective alternative, these biosimilars enhance patient access to treatment and help lower overall healthcare costs.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24244
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model